Campath(alemtuzumab Injection for intravenous use)
CAMPATH
Leukemias, lymphomas, and other hematologic cancers  Only 4 drugs may be compared at once
Remove Selected
Compare Selected
Generic Name and Formulations:
Alemtuzumab 30mg/mL; soln; for IV infusion after dilution; preservative-free.
Company:
Sanofi Genzyme Company

Select therapeutic use: Leukemias, lymphomas, and other hematologic cancers
Indications for CAMPATH:
B-cell chronic lymphocytic leukemia (B-CLL).

Adult:
Premedicate with antihistamine and acetaminophen before 1st dose, and at dose escalations. Give by IV infusion over 2 hrs. Initially 3mg per day until infusion reactions are ≤ grade 2, then increase to 10mg per day until infusion reactions are ≤ grade 2, then to maintenance 30mg/day three times per week (on alternate days); duration of therapy (including escalation): 12 weeks. Do not exceed max single dose 30mg/dose or 90mg/week. Give prophylactic antibiotics and antivirals during treatment and for at least 2 months after completion or until CD4+ counts resolve (whichever occurs later). Dose adjustments for neutropenia and thrombocytopenia: see literature. Retitrate if therapy interrupted for ≥7 days.

Children:
Not recommended.

Warnings/Precautions:
Discontinue dose for autoimmune or recurrent/persistent severe cytopenias (except lymphopenia). Withhold dose for severe cytopenias (except lymphopenia), grade 3 or 4 infusion reactions, serious infections, or during antiviral treatment for cytomegalovirus (CMV) infection or confirmed CMV viremia. Obtain CBCs, platelet counts weekly, assess CD4+ counts after treatment until recovery to ≥200cells/µL. Monitor for infusion reactions; CMV infection (continue for 2 months after therapy ends). Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:
Avoid live virus vaccines (after recent therapy). May interfere with tests using antibodies. Irradiate any blood products given (GVHD may occur).

Pharmacological Class:
Monoclonal antibody, CD52 (recombinant, humanized).

Adverse Reactions:
See full labeling. Infusion reactions, cytopenias (eg, neutropenia, lymphopenia, thrombocytopenia, anemia), infections (eg, CMV), nausea, emesis, diarrhea, insomnia, anxiety; others.

How Supplied:
Single-use vials—1, 3